New hope for Platinum-Resistant ovarian cancer: ONC201 and paclitaxel combo trial launches

NCT ID NCT04055649

Recruiting now Disease control Sponsor: Ira Winer Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 trial tests whether adding the experimental drug ONC201 to standard chemotherapy (paclitaxel) can help women with ovarian, fallopian tube, or peritoneal cancer that has stopped responding to platinum-based treatments. About 62 participants will receive the combination to see if it shrinks tumors and how safe it is. The goal is to find a better option for this hard-to-treat cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ONC201 and paclitaxel
What this could lead to: If successful, this combination could offer a new treatment option for women with ovarian cancer that no longer responds to standard platinum-based chemotherapy.
What could go wrong: This is an early Phase 2 trial with only 62 participants, so results may not apply to everyone. The drug combination may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALIGNANT OVARIAN EPITHELIAL TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fallopian tube cancer fallopian tube carcinoma fallopian tube neoplasm malignant epithelial tumor of ovary ovarian cancer ovarian carcinoma primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MALIGNANT OVARIAN EPITHELIAL TUMOR PLATINUM-RESISTANT FALLOPIAN TUBE CARCINOMA PLATINUM-RESISTANT OVARIAN CARCINOMA PLATINUM-RESISTANT PRIMARY PERITONEAL CARCINOMA RECURRENT FALLOPIAN TUBE CARCINOMA RECURRENT OVARIAN CARCINOMA RECURRENT PRIMARY PERITONEAL CARCINOMA REFRACTORY FALLOPIAN TUBE CARCINOMA REFRACTORY OVARIAN CARCINOMA REFRACTORY PRIMARY PERITONEAL CARCINOMA

Contacts and locations

Locations

Barbara Ann Karmanos Cancer Institute
RECRUITING

Detroit, Michigan, 48201, United States
Karmanos Cancer Institute at McLaren Flint
RECRUITING

Flint, Michigan, 48532, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.